HomeANTH • OTCMKTS
Anthera Pharmaceuticals Inc
$0.00
Mar 21, 8:10:00 PM GMT-4 · USD · OTCMKTS · Disclaimer
StockUS listed securityUS headquartered
Previous close
$0.00
Market cap
30.00 USD
Avg Volume
867.00
P/E ratio
-
Dividend yield
-
Primary exchange
OTCMKTS
Market news
Financials
Income Statement
Revenue
Net income
(USD)2017Y/Y change
Revenue
Operating expense
7.94M-28.30%
Net income
-26.87M51.60%
Net profit margin
Earnings per share
-3.8070.53%
EBITDA
-36.15M36.48%
Effective tax rate
Total assets
Total liabilities
(USD)2017Y/Y change
Cash and short-term investments
2.20M-89.46%
Total assets
3.67M-84.35%
Total liabilities
9.17M-13.70%
Total equity
-5.50M
Shares outstanding
23.40M
Price to book
-0.00
Return on assets
-167.77%
Return on capital
-619.42%
Net change in cash
(USD)2017Y/Y change
Net income
-26.87M51.60%
Cash from operations
-36.90M24.57%
Cash from investing
Cash from financing
18.25M-22.58%
Net change in cash
-18.65M28.58%
Free cash flow
-23.15M18.17%
About
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
Founded
2004
Employees
21
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
Search
Clear search
Close search
Google apps
Main menu